Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Kristine Freude

BrainStem, Denmark

Title: Induced pluripotent stem cell models for Alzheimer's disease

Biography

Biography: Kristine Freude

Abstract

Alzheimer’s Disease (AD) is the most common cause of dementia with currently no curative treatments available. To combat this disease it is crucial to understand the precise cellular disease pathology in order to define new targets for intervention. We have built a human induced pluripotent stem cell platform enabling us to study the disease mechanisms in the relevant target cells: human neurons, astrocytes and microglia. Our focus is on PSEN1, APP and sporadic forms of AD. For all of our lines with defined mutations we have generated CRISPR-Cas9 gene edited controls replacing the mutant nucleotide and generating isogenic controls. Our studies have so far revealed abnormal cristae formation in mitochondria accompanied by aberrant mitochondrial distribution and mitochondrial respiration deficiency. Other cellular phenotypes revealed abnormal ultrastructure’s of the Golgi Apparatus (GA), with shortened and dilated cisternae and increased surface area. The GA’s were scattered around the nuclei, indicating GA fragmentation. Furthermore reduced synaptic density and glutamine metabolic defects were part of the disease phenotypes. All of the observed cellular phenotypes were rescued in CRISPR-Cas9 generated isogenic controls, indicating a clear connection to the mutation. Moreover, mitochondria deficits, metabolic disturbances and synaptic deficiencies are considered early disease phenotypes, which can be recapitulated in our in vitro patient specific disease models making them attractive for drug target development for early interventions.